PMDA drug package insert
リベルサス錠3mg
PMDA Prescription drug · ノボ ノルディスク ファーマ株式会社 · package insert May 22, 2026
Key facts
| Brand names | リベルサス錠3mg, リベルサス錠7mg, リベルサス錠14mg |
|---|---|
| Nonproprietary names | セマグルチド（遺伝子組換え） |
| Companies | 製造販売元／ノボ ノルディスク ファーマ株式会社, 販売提携／MSD 株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 2型糖尿病治療剤 経口GLP-1受容体作動薬 |
| Therapeutic category codes | 872499 |
| YJ codes | 2499014F1021, 2499014F2028, 2499014F3024 |
| Approval numbers | 30200AMX00513000, 30200AMX00514000, 30200AMX00515000 |
| Package insert edition | 第6版 |
| Package insert date | May 22, 2026 |
| PMDA document key | 620023_2499014F1021_1 |
| PMDA company code | 620023 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- 1–9 Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: